Sanofi SA SNY reported Wednesday new data from a Phase 2 study in relapsing multiple sclerosis.
What Happened: The company’s CD40L antibody, frexalimab, demonstrated sustained reduction of disease activity. It also demonstrated favorable tolerability after nearly one year in participants with relapsing multiple sclerosis.
"These 48-week data showed that treatment with frexalimab resulted in further decreases in the number of lesions and a sustained reduction in disease activity. The preliminary clinical results are promising with a very low annual relapse rate," said Patrick Vermersch.
Also Read: In Heart Burn Drug Zantac’s Litigation Saga, Sanofi Nears Settlement in Major Lawsuit Cluster.
Results of the phase 2 OLE at week 48 showed:
- 96% of patients who continued receiving high-dose frexalimab. Eighty-seven percent of those who continued receiving low-dose frexalimab were free of Gd+ T1 lesions at week 48, respectively.
- Additionally, among patients who switched from placebo to high and low-dose frexalimab at the start of the open-label extension (OLE) at week 12, declines were seen at Week 24, and 90% and 92% were free of Gd+ T1 lesions at week 48, respectively.
- The number of Gd+ T1-lesions (mean [SD]) remained low in participants who continued receiving frexalimab (high dose: 0.0 [0.2]; low dose: 0.2 [0.5]) and continued to decline in those who switched from placebo to frexalimab at week 12 (high dose: 0.2 [0.6]; low dose: 0.1 [0.3]).
- The number and volume change of new or enlarging Gd+ T2-lesions remained low through week 48.
- Lymphocyte counts remained stable.
- Participants who continued receiving high-dose frexalimab experienced a low annualized relapse rate (ARR) of 0.04 over the 48-week treatment period. Up to 96% were free of relapses.
- ARR in the initial low-dose arm was 0.22, and ARR in patients who switched to high and low-dose frexalimab were 0.09 and 0.40, respectively, through week 48.
- Frexalimab was generally well-tolerated through week 48.
Price Action: SNY shares are up 0.37% at $45.97 on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.